

The following slides were used in connection with a presentation to employees on October 15, 2014:

Auxilium & Endo: A Compelling Combination

Rajiv De Silva
October 15, 2014



©2014 Endo Pharmaceuticals Inc. All rights reserved.

ADDITIONAL INFORMATION

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposed business combination transaction between Endo International plc ("Endo") and Auxilium Pharmaceuticals, Inc. ("Auxilium"). In furtherance of this proposed transaction, Endo and Auxilium intend to file one or more registration statements, prospectuses, proxy statements or other documents with the U.S. Securities and Exchange Commission ("SEC"). This communication is not a substitute for any registration statement, prospectus, proxy statement or other document Endo and/or Auxilium file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF AUXILIUM ARE URGED TO READ THE REGISTRATION STATEMENT, PROSPECTUS, PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The definitive proxy statement (when available) will be mailed to stockholders of Auxilium. Investors and security holders will be able to obtain free copies of these documents (when available) and other documents filed with the SEC by Endo through the web site maintained by the SEC at <http://www.sec.gov>.

CERTAIN INFORMATION REGARDING PARTICIPANTS

Endo and Auxilium and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Auxilium stockholders with respect to the proposed transaction under the rules of the SEC. Security holders may obtain information regarding the names and interests of Endo's directors and executive officers in Endo Health Solutions Inc.'s ("EHSI") Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 3, 2014, and Endo's proxy statement for the 2014 Annual General Meeting of Shareholders, which was filed with the SEC on April 29, 2014. Security holders may obtain information regarding the names and interests of Auxilium's directors and executive officers in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on February 28, 2014, Auxilium's proxy statement for the 2014 Annual Meeting of Stockholders, which was filed with the SEC on April 10, 2014, and the materials that will be filed with the SEC in connection with the proposed transaction. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the proxy statement and other relevant materials to be filed with the SEC when they become available.

All trademarks, service marks, trade names, product names and logos appearing in this presentation are the property of their respective owners. XIAFLEX[®], Testim[®], TESTOPEL[®], TENDRA[®], dex[®], Osbon[®], ErecAid[®], STRIANT[®], Theo24[®], Semprex[®], Dilatrate[®], SR and robaxin[®] and the related logos are the property of Auxilium. All other trademarks, service marks, trade names, product names and logos appearing in this presentation are the property of Endo.



Forward-Looking Statements

This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. These forward-looking statements include, but are not limited to, statements regarding the proposed transaction, the financing of the proposed transaction, Endo's and Auxilium's expected future performance (including expected results of operations and financial guidance) and the combined company's future financial condition, operating results, strategy and plans. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's and Auxilium's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Although Endo and Auxilium believe that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or information in this communication. Investors should note that many factors, as more fully described in the documents filed by Endo with the SEC and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval ("SEDAR"), and by Auxilium with the SEC including under the caption "Risk Factors" in EHSI's Form 10-K and Endo's Form 10-Q and Form 8-K filings, and in Auxilium's 10-K, 10-Q and 8-K filings, as applicable, and as otherwise enumerated herein or therein, could affect future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in this communication. Important factors that, individually or in the aggregate, could cause actual results to differ materially from expected and historical results include, but are not limited to:

- the failure to receive the required approval from Auxilium stockholders and applicable government and regulatory authorities (and the terms of those approvals);
- the risk that a condition to closing contemplated by the merger agreement may not be satisfied or waived;
- the ultimate outcome and results of integrating the operations of Endo and Auxilium, the ultimate outcome of Endo's operating strategy applied to Auxilium and the ultimate ability to realize synergies and the magnitude of such synergies;
- the effects of the business combination of Endo and Auxilium, including the combined company's future financial condition, operating results, strategy and plans;
- Endo's ability to achieve significant upside potential for shareholders by accelerating the growth of XIAFLEX[®] and other products of the resultant combined company;
- Endo's ability to sustain and grow revenues and cash flow from operations in its markets and to maintain and grow its customer base, the need for innovation and the related capital expenditures and the unpredictable economic conditions in the United States and other markets;
- the impact of competition from other market participants;
- the development and commercialization of new products;
- the effects of governmental regulation on our business or potential business combination transaction;
- the availability and access in general, of funds to meet Endo's debt obligations prior to or when they become due and to fund its operations and necessary capital expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets; and
- Endo's ability to comply with all covenants in its indentures and credit facilities, any violation of which, if not cured in a timely manner, could trigger a default of its other obligations under cross-default provisions.

All forward-looking statements attributable to Endo or Auxilium or any person acting on either of their behalf are expressly qualified in their entirety by this cautionary statement. These forward-looking statements speak only as of the date hereof. Neither Endo nor Auxilium assumes any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.



Who is Endo International plc?




Endo International plc is a global specialty healthcare company focused on improving patients lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic and device products through its operating companies.

Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, PA.





Company History



Endo's Vision and Key Values

To become a leading global specialty healthcare company that improves lives while creating value



CUSTOMER FOCUS

Commit to creating value

RESULTS DRIVEN

Perform to exceed expectations

LEADERSHIP

Aspire to excellence

TEAMWORK

Unite to deliver superior results


INNOVATION & CONTINUOUS IMPROVEMENT

Drive for relentless progress




Our Roadmap to Success

- Be nimble and entrepreneurial
- Be the best manager of assets
- Deliver relevant products to market
- Be efficient acquirers and integrators of new businesses
- Stay a step ahead and outperform our competitors
- Embrace high performance standards
- Act in a compliant and ethical manner



Expanding Presence Globally



Endo and Auxilium: A Compelling Combination

- Creates value for patients, customers and shareholders
- Establishes a leading branded specialty pharmaceutical business with a focus in men's healthcare, pain and rare/orphan diseases
- Accelerates organic growth and maximizes value of key products leveraging strengths of combined company and economies of scale
 - XIAFLEX® (for Dupuytren's Contracture and Peyronie's Disease)
 - STENDRA®
 - TESTOPEL®
 - AVEED®
- Expands R&D capabilities and development programs
 - XIAFLEX® new potential indications
 - BEMA buprenorphine
- Buildson a platform with enhancedfinancialflexibility, provenM&A capabilitiesand an establishedcorporatestructure






Select Highlights of Complementary Product Portfolio

Men's Health / Urology

Orthopedics / Pain

Other Specialty



©2014 Endo Pharmaceuticals Inc. All rights reserved.

What Does This Mean For Employees of Auxilium?

- Bringing our two organizations together will require us to look for efficiencies in overlapping areas
 - There will be some workforce reductions
 - Commitment to transparency, fairness and speed in integration post-close
- True value of combination is in accelerating long-term growth potential
 - Commitment to required investment
 - Aspiration to retain as many high performing employees as possible
- Remain focused on what you can control—performance against your goals



Next Steps

- We expect the close of this transaction to take place in first half of 2015, subject to:
 - Regulatory approval in the U.S.
 - Auxilium stockholder vote
 - Other customary closing conditions
- Until the closing of this transaction, Endo and Auxilium will continue to operate as independent companies
- While integration planning will commence, no decisions can begin prior to the close of the transaction
 - Structure of integration planning team will be communicated shortly
 - Team leads will be appointed from both companies



QUESTIONS?



